Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

MONTREAL, Aug. 25, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company, today announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound, THRV-1268, at the upcoming European Society of Cardiology (ESC) Congress 2025,...